Zheng YC - Search Results

1

Correction to "Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective".

Dai XJ, Liu Y, Xiong XP, Xue LP, Zheng YC, Liu HM. Dai XJ, et al. Among authors: zheng yc. J Med Chem. 2021 May 13;64(9):6412. doi: 10.1021/acs.jmedchem.1c00570. Epub 2021 Apr 19. J Med Chem. 2021. PMID: 33871987 No abstract available.

2

Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.

Duan Y, Qin W, Suo F, Zhai X, Guan Y, Wang X, Zheng Y, Liu H. Duan Y, et al. Bioorg Med Chem. 2018 Dec 15;26(23-24):6000-6014. doi: 10.1016/j.bmc.2018.10.037. Epub 2018 Oct 29. Bioorg Med Chem. 2018. PMID: 30448189

3

Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).

Li Z, Ding L, Li Z, Wang Z, Suo F, Shen D, Zhao T, Sun X, Wang J, Liu Y, Ma L, Zhao B, Geng P, Yu B, Zheng Y, Liu H. Li Z, et al. Acta Pharm Sin B. 2019 Jul;9(4):794-808. doi: 10.1016/j.apsb.2019.01.001. Epub 2019 Jan 5. Acta Pharm Sin B. 2019. PMID: 31384539 Free PMC article.

4

Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.

Dai XJ, Liu Y, Xiong XP, Xue LP, Zheng YC, Liu HM. Dai XJ, et al. Among authors: zheng yc. J Med Chem. 2020 Dec 10;63(23):14197-14215. doi: 10.1021/acs.jmedchem.0c00919. Epub 2020 Sep 30. J Med Chem. 2020. PMID: 32931269 Review.

5

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.

Dai XJ, Liu Y, Xue LP, Xiong XP, Zhou Y, Zheng YC, Liu HM. Dai XJ, et al. Among authors: zheng yc. J Med Chem. 2021 Mar 11;64(5):2466-2488. doi: 10.1021/acs.jmedchem.0c02176. Epub 2021 Feb 23. J Med Chem. 2021. PMID: 33619958 Review.

6

Correction to "Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1".

Dai XJ, Liu Y, Xue LP, Xiong XP, Zhou Y, Zheng YC, Liu HM. Dai XJ, et al. Among authors: zheng yc. J Med Chem. 2021 May 13;64(9):6410-6411. doi: 10.1021/acs.jmedchem.1c00568. Epub 2021 Apr 19. J Med Chem. 2021. PMID: 33871995 No abstract available.

7

Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness.

Zhao LJ, Li YY, Zhang YT, Fan QQ, Ren HM, Zhang C, Mardinoglu A, Chen WC, Pang JR, Shen DD, Wang JW, Zhao LF, Zhang JY, Wang ZY, Zheng YC, Liu HM. Zhao LJ, et al. Among authors: zheng yc. EMBO Rep. 2021 Aug 4;22(8):e50922. doi: 10.15252/embr.202050922. Epub 2021 May 31. EMBO Rep. 2021. PMID: 34060205 Free PMC article.

8

Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Shen DD, Bi YP, Pang JR, Zhao LJ, Zhao LF, Gao Y, Wang B, Liu HM, Liu Y, Wang N, Zheng YC, Liu HM. Shen DD, et al. Among authors: zheng yc. Cell Mol Life Sci. 2022 Jul 11;79(8):413. doi: 10.1007/s00018-022-04431-x. Cell Mol Life Sci. 2022. PMID: 35819633 Free PMC article. Review.

9

Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells.

Dai XJ, Zhao LJ, Yang LH, Guo T, Xue LP, Ren HM, Yin ZL, Xiong XP, Zhou Y, Ji SK, Liu HM, Liu HM, Liu Y, Zheng YC. Dai XJ, et al. Among authors: zheng yc. J Med Chem. 2023 Mar 23;66(6):3896-3916. doi: 10.1021/acs.jmedchem.2c01593. Epub 2023 Mar 1. J Med Chem. 2023. PMID: 36856685

10

Degraders in epigenetic therapy: PROTACs and beyond.

Dai XJ, Ji SK, Fu MJ, Liu GZ, Liu HM, Wang SP, Shen L, Wang N, Herdewijn P, Zheng YC, Wang SQ, Chen XB. Dai XJ, et al. Among authors: zheng yc. Theranostics. 2024 Jan 27;14(4):1464-1499. doi: 10.7150/thno.92526. eCollection 2024. Theranostics. 2024. PMID: 38389844 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

280 results

Search Page